130 related articles for article (PubMed ID: 8573421)
1. Tiludronate: bone pharmacology and safety.
Bonjour JP; Ammann P; Barbier A; Caverzasio J; Rizzoli R
Bone; 1995 Nov; 17(5 Suppl):473S-477S. PubMed ID: 8573421
[TBL] [Abstract][Full Text] [Related]
2. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density.
Ammann P; Rizzoli R; Caverzasio J; Shigematsu T; Slosman D; Bonjour JP
J Bone Miner Res; 1993 Dec; 8(12):1491-8. PubMed ID: 8304051
[TBL] [Abstract][Full Text] [Related]
3. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?
Delmas PD; Vergnaud P; Arlot ME; Pastoureau P; Meunier PJ; Nilssen MH
Bone; 1995 Jun; 16(6):603-10. PubMed ID: 7669436
[TBL] [Abstract][Full Text] [Related]
4. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.
Murakami H; Takahashi N; Sasaki T; Udagawa N; Tanaka S; Nakamura I; Zhang D; Barbier A; Suda T
Bone; 1995 Aug; 17(2):137-44. PubMed ID: 8554921
[TBL] [Abstract][Full Text] [Related]
5. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
6. Tiludronate. A new treatment for an old ailment: Paget's disease of bone.
Morales-Piga A
Expert Opin Pharmacother; 1999 Nov; 1(1):157-70. PubMed ID: 11249559
[TBL] [Abstract][Full Text] [Related]
7. Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy.
Murakami H; Nakamura T; Tsurukami H; Abe M; Barbier A; Suzuki K
J Bone Miner Res; 1994 Sep; 9(9):1355-64. PubMed ID: 7529459
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats.
Ohnishi H; Nakamura T; Narusawa K; Murakami H; Abe M; Barbier A; Suzuki K
Bone; 1997 Oct; 21(4):335-43. PubMed ID: 9315337
[TBL] [Abstract][Full Text] [Related]
9. Skeletal safety of tiludronate.
Neer RM
Bone; 1995 Nov; 17(5 Suppl):501S-503S. PubMed ID: 8573427
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate effects in rat unloaded hindlimb bone loss model: three-dimensional microcomputed tomographic, histomorphometric, and densitometric analyses.
Barou O; Lafage-Proust MH; Martel C; Thomas T; Tirode F; Laroche N; Barbier A; Alexandre C; Vico L
J Pharmacol Exp Ther; 1999 Oct; 291(1):321-8. PubMed ID: 10490920
[TBL] [Abstract][Full Text] [Related]
11. Ultrastructural properties of bone mineral of control and tiludronate-treated osteoporotic rat.
Rohanizadeh R; LeGeros RZ; Bohic S; Pilet P; Barbier A; Daculsi G
Calcif Tissue Int; 2000 Oct; 67(4):330-6. PubMed ID: 11000348
[TBL] [Abstract][Full Text] [Related]
12. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts.
Murakami H; Takahashi N; Tanaka S; Nakamura I; Udagawa N; Nakajo S; Nakaya K; Abe M; Yuda Y; Konno F; Barbier A; Suda T
Bone; 1997 May; 20(5):399-404. PubMed ID: 9145236
[TBL] [Abstract][Full Text] [Related]
13. Bone mass homeostasis and bisphosphonate action.
Rodan GA
Bone; 1997 Jan; 20(1):1-4. PubMed ID: 8988341
[TBL] [Abstract][Full Text] [Related]
14. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
15. Effects of tiludronate on bone loss in paraplegic patients.
Chappard D; Minaire P; Privat C; Berard E; Mendoza-Sarmiento J; Tournebise H; Basle MF; Audran M; Rebel A; Picot C
J Bone Miner Res; 1995 Jan; 10(1):112-8. PubMed ID: 7747617
[TBL] [Abstract][Full Text] [Related]
16. Effect of ovariectomy on intraosseous vascularization and bone remodelling in rats: action of tiludronate.
Laroche M; Barbier A; Ludot I; Vernhet C; Thiechart M; Viguier G; Mazieres B
Osteoporos Int; 1996; 6(2):127-9. PubMed ID: 8704350
[TBL] [Abstract][Full Text] [Related]
17. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
van der Pluijm G; Binderup L; Bramm E; van der Wee-Pals L; De Groot H; Binderup E; Löwik C; Papapoulos S
J Bone Miner Res; 1992 Aug; 7(8):981-6. PubMed ID: 1442212
[TBL] [Abstract][Full Text] [Related]
18. Tiludronate inhibits interleukin-6 synthesis in osteoblasts: inhibition of phospholipase D activation in MC3T3-E1 cells.
Tokuda H; Kozawa O; Harada A; Uematsu T
J Cell Biochem; 1998 Jun; 69(3):252-9. PubMed ID: 9581864
[TBL] [Abstract][Full Text] [Related]
19. Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction.
Motoie H; Nakamura T; O'uchi N; Nishikawa H; Kanoh H; Abe T; Kawashima H
J Bone Miner Res; 1995 Jun; 10(6):910-20. PubMed ID: 7572315
[TBL] [Abstract][Full Text] [Related]
20. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.
Yu X; Schøller J; Foged NT
Bone; 1996 Oct; 19(4):339-45. PubMed ID: 8894139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
